Ключевые слова
Как цитировать
Аннотация
Рак молочной железы (РМЖ) - одна из основных причин метастазирования в головной мозг у женщин, частота которого увеличивается по мере совершенствования программ нейровизуализации и увеличения продолжительности жизни вследствие улучшения возможностей противоопухолевой лекарственной терапии. Несмотря на постоянное развитие новых методов локальной и системной терапии, лечение пациентов с метастазами РМЖ в головной мозг (МГМ) остается сложной задачей. Стратегия лечения должна основываться на мультидисциплинарных решениях с учетом рисков и преимущества каждого терапевтического метода в отношении увеличения выживаемости, локального контроля и сохранения качества жизни. В представленном обзоре рассматриваются вопросы лечения пациентов с метастазами РМЖ в головной мозг в контексте современных данных научной литературы.
Библиографические ссылки
American Cancer Society. Cancer Facts & Figures. 2020. https: // doi: www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2020/cancer-facts-and-figures-2020.pdf
Банов С.М., Голанов А.В., Ветлова Е.Р. и др. Результаты радиохирургического лечения пациентов с метастатическим поражением головного мозга // Вопросы онкологии. 2017;63:52–61.
Gavrilovic IT, Posner JB. Brain metastases: epidemiology and pathophysiology // J Neurooncol. 2005;75:5–14. https: // doi: 10.1007/s11060-004-8093-6
Komorowski AS, Warner E, MacKay HJ et al. Incidence of Brain Metastases in Nonmetastatic and Metastatic Breast Cancer: Is There a Role for Screening? // Clin Breast Cancer. 2020;20: е54-е64. https: // doi: 10.1016/j.clbc.2019.06.007
Sperduto PW, Kased N, Roberge D et al. The effect of tumor subtype on the time from primary diagnosis to development of brain metastases and survival in patients with breast cancer // J Neurooncol. 2013;112:467–72. https: // doi: 10.1007/s11060-013-1083-9
Subbiah IM, Lei X, Weinberg JS et al. Validation and Development of a Modified Breast Graded Prognostic Assessment as a Tool for Survival in Patients With Breast Cancer and Brain Metastases // JCO. 2015;33:2239–45. https: // doi: 10.1200/JCO.2014.58.8517
Jandial R, Hoshide R, Waters JD, Somlo G. Operative and Therapeutic Advancements in Breast Cancer Metastases to the Brain // Clin Breast Cancer. 2018;18:e455–e467. https: // doi: 10.1016/j.clbc.2017.10.002
Lockman PR, Mittapalli RK, Taskar KS et al. Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer // Clin Cancer Res. 2010;16:5664–78. https: // doi: 10.1158/1078-0432.CCR-10-1564
Muacevic A, Wowra B, Siefert A et al. Microsurgery plus whole brain irradiation versus Gamma Knife surgery alone for treatment of single metastases to the brain: a randomized controlled multicentre phase III trial // J Neurooncol. 2008;87:299–307. https: // doi: 10.1007/s11060-007-9510-4
Roos DE, Smith JG, Stephens SW. Radiosurgery versus surgery, both with adjuvant whole brain radiotherapy, for solitary brain metastases: a randomised controlled trial // Clin Oncol (R Coll Radiol). 2011;23:646–51. https: // doi: 10.1016/j.clon.2011.04.009
Kondziolka D, Patel A, Lunsford L, Kassam A, Flickinger JC. Stereotactic radiosurgery plus whole brain radiotherapy versus radiotherapy alone for patients with multiple brain metastases // International Journal of Radiation Oncology Biology Physics. 1999;45:427–34. https: // doi: 10.1016/S0360-3016(99)00198-4
Andrews DW, Scott CB, Sperduto PW et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial // The Lancet. 2004;363:1665–72. https: // doi: 10.1016/S0140-6736(04)16250-8
Aoyama H, Shirato H, Tago M et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial // JAMA. 2006;295:2483–91. https: // doi: 10.1001/jama.295.21.2483
Chang EL, Wefel JS, Hess KR et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial // The Lancet Oncology. 2009;10:1037–44. https: // doi: 10.1016/S1470-2045(09)70263-3
Kocher M, Soffietti R, Abacioglu U et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study // J Clin Oncol. 2011;29:134–41. https: // doi: 10.1200/JCO.2010.30.1655
Sahgal A, Aoyama H, Kocher M et al. Phase 3 trials of stereotactic radiosurgery with or without whole-brain radiation therapy for 1 to 4 brain metastases: individual patient data meta-analysis // Int J Radiat Oncol Biol Phys. 2015;91:710–7. https: // doi: 10.1016/j.ijrobp.2014.10.024
Yamamoto M, Serizawa T, Shuto T et al. Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study // Lancet Oncol. 2014;15:387–95. https: // doi: 10.1016/S1470-2045(14)70061-0
Ogura M, Mitsumori M, Okumura S et al. Radiation therapy for brain metastases from breast cancer // Breast Cancer. 2003;10:349–55. https: // doi: 10.1007/BF02967656
Kondziolka D, Kano H, Harrison GL et al. Stereotactic radiosurgery as primary and salvage treatment for brain metastases from breast cancer. Clinical article // J Neurosurg. 2011;114:792–800. https: // doi: 10.3171/2010.8. JNS10461
Xu Z, Schlesinger D, Toulmin S, Rich T, Sheehan J. Impact of triple-negative phenotype on prognosis of patients with breast cancer brain metastases // Int J Radiat Oncol Biol Phys. 2012;84:612–8. https: // doi: 10.1016/j.ijrobp.2011.12.054
Gao C, Wang F, Suki D et al. Effects of systemic therapy and local therapy on outcomes of 873 breast cancer patients with metastatic breast cancer to brain: MD Anderson Cancer Center experience // Int J Cancer. 2020;1:1–10. https: // doi: 10.1002/ijc.33243
Soffietti R, Abacioglu U, Baumert B et al. Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO) // Neuro-oncology. 2017;19:162–74. https: // doi: 10.1093/neuonc/now241
Дашян Г.А., Семиглазов В.Ф., Криворотько П.В. и др. Роль таргетной терапии в лечении метастатического HER-2-положительного рака молочной железы с поражением головного мозга // Опухоли женской репродуктивной системы. 2016;12:46–51.
Romuald Le Scodan, Ludivine Jouanneau, Christophe Massard et al. Brain metastases from breast cancer: prognostic significance of HER-2 overexpression, effect of trastuzumab and cause of death // BMC Cancer. 2011;11:395.
Larsen PB, Kümler I, Nielsen DL. A systematic review of trastuzumab and lapatinib in the treatment of women with brain metastases from HER2-positive breast cancer // Cancer Treat Rev. 2013;39:720–7. https: // doi: 10.1016/j.ctrv.2013.01.006
Park YH, Park MJ, Ji SH et al. Trastuzumab treatment improves brain metastasis outcomes through control and durable prolongation of systemic extracranial disease in HER2-overexpressing breast cancer patients // Br J Cancer. 2009;100:894–900. https: // doi: 10.1038/sj.bjc.6604941
Swain SM, Baselga J, Miles D et al. Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA // Ann Oncol. 2014;25:1116–21. https: // doi: 10.1093/annonc/mdu133
Krop IE, Lin NU, Blackwell K et al. Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA // Ann Oncol. 2015;26:113–9. https: // doi: 10.1093/annonc/mdu486
Ricciardi GRR, Russo A, Franchina T et al. Efficacy of T-DM1 for leptomeningeal and brain metastases in a HER2 positive metastatic breast cancer patient: new directions for systemic therapy — a case report and literature review // BMC Cancer. 2018;18:97. https: // doi: 10.1186/s12885-018-3994-5
Jacot W, Pons E, Frenel J-S et al. Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases // Breast Cancer Res Treat. 2016;157:307–18. https: // doi: 10.1007/s10549-016-3828-6
Bachelot T, Romieu G, Campone M et al. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study // The Lancet Oncology. 2013;14:64–71. https: // doi: 10.1016/S1470-2045(12)70432-1
Freedman RA, Gelman RS, Anders CK et al. TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients with Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases // J Clin Oncol. 2019;37:1081–9. https: // doi: 10.1200/JCO.18.01511
Awada A, Colomer R, Inoue K et al. Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial // JAMA Oncol. 2016;2:1557–64. https: // doi: 10.1001/jamaoncol.2016.0237
Awada A, Brufsky A, Saura C et al. Impact of neratinib on development and progression of central nervous system metastases in patients with HER2-positive metastatic breast cancer: Findings from the NALA, NEfERT-T, and TBCRC 022 trials. https: // www. pumabiotechnology. Com/d ocs/1 21219_Awada_CNS_SABCS_2019_poster_10_Dec_2019_FINAL.pdf
Colomer R, Cosos D, Del Campo JM et al. Brain metastases from breast cancer may respond to endocrine therapy // Breast Cancer Res Treat. 1988;12:83–6. https: // doi: 10.1007/BF01805745
Kennecke H, Yerushalmi R, Woods R et al. Metastatic behavior of breast cancer subtypes // J Clin Oncol. 2010;28:3271–7. https: // doi: 10.1200/JCO.2009.25.9820
Raub TJ, Wishart GN, Kulanthaivel P et al. Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft // Drug Metab Dispos. 2015;43:1360–71. https: // doi: 10.1124/dmd.114.062745
Anders CK, Le Rhun E, Bachelot TD et al. A phase II study of abemaciclib in patients (pts) with brain metastases (BM) secondary to HR+, HER2- metastatic breast cancer (MBC) // JCO. 2019;37:1017. https: // doi: 10.1200/JCO.2019.37.15_suppl.1017
Boogerd W, Dalesio O, Bais EM, van der Sande JJ. Response of brain metastases from breast cancer to systemic chemotherapy // Cancer. 1992;69:972–80. https: // doi: 10.1002/1097-0142(19920215)69:4<972::AID-CNCR2820690423>3.0.CO;2-P
Franciosi V, Cocconi G, Michiara M et al. Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma // Cancer. 1999;85:1599–605. https: // doi: 10.1002/(SICI)1097-0142(19990401)85:7<1599: AID-CNCR23>3.0.CO;2-#
Lu Y-S, Chen TW-W, Lin C-H et al. Bevacizumab preconditioning followed by Etoposide and Cisplatin is highly effective in treating brain metastases of breast cancer progressing from whole-brain radiotherapy // Clin Cancer Res. 2015;21:1851–8. https: // doi: 10.1158/1078-0432.CCR-14-2075
Lin NU, Gelman RS, Younger WJ et al. Phase II trial of carboplatin © and bevacizumab (BEV) in patients (pts) with breast cancer brain metastases (BCBM) // JCO. 2013;31:513. https: // doi: 10.1200/jco.2013.31.15_suppl.513
Adamo V, Ricciardi GRR, Giuffrida D et al. Eribulin mesylate use as third-line therapy in patients with metastatic breast cancer (VESPRY): a prospective, multicentre, observational study // Ther Adv Med Oncol. 2019;11:1758835919895755. https: // doi: 10.1177/1758835919895755
Колядина И.В., Булавина И.С., Петкау В.В. и др. Потенциал использования эрибулина при метастатическом поражении головного мозга у больных раком молочной железы: научные предпосылки и российский клинический опыт // Современная онкология. 2019;21:17–24. https: // doi: 10.26442/18151434.2019.2.190395
Sirvén MB, Fernández-Ortega A, Stradella A et al. Real-world efficacy and safety of eribulin in advanced and pretreated HER2-negative breast cancer in a Spanish comprehensive cancer center // BMC Pharmacol Toxicol. 2019;20:68. https: // doi: 10.1186/s40360-019-0367-x
Cortés J, Rugo HS, Awada A et al. Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial // Breast Cancer Res Treat. 2017;165:329–41. https: // doi: 10.1007/s10549-017-4304-7
Kumthekar P, Tang S-C, Brenner AJ et al. ANG1005, a brain penetrating peptide-drug conjugate, shows activity in patients with breast cancer with leptomeningeal carcinomatosis and recurrent brain metastases // Clin Cancer Res. 2020. https: // doi: 10.1158/1078-0432.CCR-19-3258
Chamberlain MC, Baik CS, Gadi VK et al. Systemic therapy of brain metastases: non-small cell lung cancer, breast cancer, and melanoma // Neuro-oncology. 2017;19: i1-i24. https: // doi: 10.1093/neuonc/now197
Это произведение доступно по лицензии Creative Commons «Attribution-NonCommercial-NoDerivatives» («Атрибуция — Некоммерческое использование — Без производных произведений») 4.0 Всемирная.
© АННМО «Вопросы онкологии», Copyright (c) 2021